The DOI matches its Crossref record.
BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
Open accessAbstract
Inflammatory arthritis and especially rheumatoid arthritis (RA) is common and affects 1% of the population. The prognosis of RA remains uncertain as it runs a variable and unpredictable course. Several longitudinal studies have demonstrated the progressive course of RA and new research has emphasized the need for early intervention with disease-modifying anti-rheumatic drugs (DMARDs) to prevent long-term disability. The development of Clinical Guidelines is the first step towards earlier diagnosis and treatment. This multidisciplinary and multiprofesssional guideline on DMARDs is timely for two major reasons: first, it was necessary to update the guideline produced by the British Society for Rheumatology (BSR) 5 yrs ago; and second, it was necessary to produce a unified approach to monitoring patients on some of the DMARDs particularly methotrexate due to recent developments with the national patient safety agency. Therefore, this guideline is somewhat unique, as BSR has taken a collaborative approach with the British Association of Dermatologists (BAD) to develop this document. This comprehensive evidence-based guideline on individual DMARDs gives a framework for monitoring the effects of these drugs that will help all health-care professionals across the primary and secondary care. This guideline is to be taken in conjunction with the guideline on the management of RA (Rheumatology 2006;45:1167–9). It is generally believed that specific therapy with DMARD should commence once the diagnosis of RA is confirmed, usually within 3 months. This document will address issues related to 10 major DMARDs that are used in day-to-day clinical practice for adults with RA. This document will not address drugs such as biologics, as the guideline on these drugs have already been published. This guideline is not for use in children, and British Society for Paediatrics and Adolescent Rheumatology (BSPAR) has produced a similar guideline for children requiring the use of similar drugs for RA. This guideline is essentially for patients on monotherapy and extra caution should be taken for patients on combination therapy. The best DMARDs are those that provide the greatest efficacy with the least toxicity over the long term. It is therefore important to assess the progress of the disease and response to treatment on a regular basis. ‘Annual review’ may be an ideal way of assessing such clinical progress. Some patients require withdrawal of therapy and the two common reasons for such withdrawal are inefficacy and adverse effects. However, patients’ choice does also play a role in some cases when they prefer to withdraw therapy after being in long-term remission. Temporary withdrawal is also advised in some clinical circumstances, i.e. if patients develop an untoward side effect or in some physiological conditions, i.e. pregnancy/lactation. This is one of the major remits of this document and each drug has been described fully, as it should be used in rheumatology with appropriate recommendations from BAD where there are common indications for use between specialties. The key statements when monitoring a DMARD are: It is important to note that in addition to absolute values for any haematological or biochemical indices, a rapid unusual fall or rise or a consistent downward or upward trend in any value should prompt caution and extra vigilance. Extra caution is required before advising patients about immunizations, as live vaccines are not recommended when patients are on certain immuno modulators. Drug interactions are important and should always be weighed against the clinical need. Pregnancy and related issues such as breast-feeding must be addressed when patients are receiving a DMARD. It is necessary to be absolutely certain about the effect of the DMARD on the fetus as well as on lactation. All monitoring activity for early detection of toxicity should also be documented in case notes and the patient should be informed as well. Although side effects are not mentioned with each individual DMARD, users of this document are requested to also consult the British National Formulary (BNF) and individual drug summary of product characteristics (SPC) wherever needed. ALL patients should be provided with a patient-held booklet of their DMARD monitoring records with clear mention of all current results where appropriate. Patients should be encouraged to take part in a self-management programme to monitor their own therapy as studies have shown that patients like to be involved in their continuing care rather than just informed about the therapy. All patients should ideally be made go through a regular educational programme before prescribing the DMARD. It is desirable that some form of outcome assessment is undertaken and all contacts between the health professional and the patient for the purpose of monitoring should be taken as an opportunity for teaching and training about the role of the DMARD in RA or other similar diseases. Alth
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
Self-citationEULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
The diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 682
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem146a · Cited by 369
Self-citation
Metadata
- Authors
- Chakravarty, K., McDonald, H., Pullar, T., Taggart, A., Chalmers, R., Oliver, S., Mooney, J., Somerville, M., Bosworth, A., & Kennedy, T.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-28
- Volume
- 47
- Issue
- 6
- Pages
- 924-925
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2106550996
- Cited by
- 179
- References
- 0
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. https://app.cochat.ai/papers/10.1093/rheumatology/kel216a
- The paper
- Chakravarty, K., McDonald, H., Pullar, T., Taggart, A., Chalmers, R., Oliver, S., Mooney, J., Somerville, M., Bosworth, A., & Kennedy, T. (2008). BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. https://doi.org/10.1093/rheumatology/kel216a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.